TWST Trading Analysis - 11/02/2026 01:13 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge of TWST (Twist Bioscience) and are provided as contextual background only, separate from the data-driven analysis below.

• Twist Bioscience announced expansion of its synthetic DNA product line for AI-driven drug discovery partnerships in Q3 2026, potentially supporting long-term revenue diversification.
• Recent sector volatility in genomics and biotech names followed FDA commentary on personalized medicine regulation, creating headline risk for small-cap diagnostics firms.
• TWST reported fiscal year-end (Sept 1, 2026) with continued net losses per fundamentals, keeping investor focus on cash burn rather than near-term profitability.
• No specific earnings date catalyst was flagged in provided data, but high beta (2.48) suggests sensitivity to broad market swings into year-end.
• Context: Heavy put positioning in options (per embedded data) may reflect hedging against sector-wide biotech weakness seen in recent headlines.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for TWST:

• Trailing EPS is -2.23, confirming the company is not yet profitable (negative earnings).
• Trailing P/E is null and Forward P/E is null; PEG ratio is null — no standard valuation multiple available from data.
• Profit margins (gross, operating, net), revenue growth, ROE, and debt-to-equity are all null in the data — not computable.
• Market cap is $8,831,458,952.50 with shares outstanding of 66,301,000.00; institutional ownership is 99.70% (very high).
• Dividend yield is 0.00% (no income). Beta is 2.48 (high systemic risk).
• 52-week high is $219.71, low is $23.30; historical volatility is 111.78% (extreme).
• Analyst consensus and target mean price are null — no street view in data.
• Fundamentals (loss-making, high volatility, no margin data) diverge from mixed technicals (price near SMA clusters) and heavily bearish options sentiment.

Current Market Position

From embedded data: Daily close on 2026-10-30 was $154.26. Minute bars show 2026-11-02 12:45 close at $133.20, down from 2026-10-30 09:30 open of $162.94. Recent price action shows a drop from ~$174 (2026-10-28) to $154.26 (10-30), then intraday slide to $133.20 by 11-02 midday.

Minute bars (last 5): 12:25 $133.79, 12:30 $132.79, 12:35 $134.06, 12:40 $133.45, 12:45 $133.20 — low-volume drift lower (9,209 vol on last bar). Intraday momentum is weak/bearish.

Technical Analysis

SMA alignment: SMA 5 ($161.44) > SMA 20 ($154.39) > SMA 50 ($153.32) — short-term below mid/long, slight bearish tilt. Price ($154.26) sits just under SMA 20 and above SMA 50. RSI 51.39 = neutral momentum. MACD histogram positive (0.16) = mild bullish bias but weak. Bollinger mid $154.39; price near mid, bands wide (upper $187.65, lower $121.14) = no squeeze. 30d range $130.68–$219.71; price near lower third.

True Sentiment Analysis (Delta 40-60 Options)

From TRUE SENTIMENT OPTIONS data (2026-11-02):

Call Volume: $58,070.00 (2.70%) Put Volume: $2,079,860.00 (97.30%) Total: $2,137,930.00

Sentiment: Bearish. Only 19 of 522 options met delta filter (3.60%). Put contracts 362 vs call 36. Pure directional conviction is heavily bearish — suggests near-term downside protection / short bets. Divergence: technicals neutral (RSI ~51, MACD mildly positive) while options scream bearish.

Key Price Levels (observational only)